PMID- 28217522
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2230-8210 (Print)
IS  - 2230-9500 (Electronic)
IS  - 2230-9500 (Linking)
VI  - 21
IP  - 1
DP  - 2017 Jan-Feb
TI  - A review of clinical efficacy and safety of canagliflozin 300 mg in the 
      management of patients with type 2 diabetes mellitus.
PG  - 196-209
LID - 10.4103/2230-8210.196016 [doi]
AB  - Currently available antihyperglycemic agents, despite being effective, provide 
      inadequate glycemic control and/or are associated with side effects or 
      nonadherence. Canagliflozin, a widely used orally active inhibitor of 
      sodium-glucose cotransporter 2 (SGLT2), is a new addition to the therapeutic 
      armamentarium of glucose-lowering drugs. This review summarizes findings from 
      different clinical and observational studies of canagliflozin 300 mg in patients 
      with type 2 diabetes mellitus (T2DM). By inhibiting SGLT2, canagliflozin reduces 
      reabsorption of filtered glucose, thereby increasing urinary glucose excretion in 
      patients with T2DM. Canagliflozin 300 mg has been shown to be effective in 
      lowering glycated hemoglobin, fasting plasma glucose, and postprandial glucose in 
      patients with T2DM. Canagliflozin 300 mg also demonstrated significant reductions 
      in body weight and blood pressure and has a low risk of causing hypoglycemia, 
      when not used in conjunction with insulin and insulin secretagogues. 
      Canagliflozin 300 mg was generally well tolerated in clinical studies. The most 
      frequently reported adverse events include genital mycotic infections, urinary 
      tract infections, osmotic diuresis, and volume depletion-related events.
FAU - Prasanna Kumar, K M
AU  - Prasanna Kumar KM
AD  - Bangalore Diabetes Hospital, Bengaluru, Karnataka, India.
FAU - Ghosh, Sujoy
AU  - Ghosh S
AD  - Department of Endocrinology, Institute of Post Graduate Medical Education and 
      Research, Kolkata, West Bengal, India.
FAU - Canovatchel, William
AU  - Canovatchel W
AD  - Janssen Research and Development, LLC, Raritan, NJ, USA.
FAU - Garodia, Nishant
AU  - Garodia N
AD  - Janssen Medical Affairs, Mumbai, Maharashtra, India.
FAU - Rajashekar, Sujith
AU  - Rajashekar S
AD  - Janssen Medical Affairs, Mumbai, Maharashtra, India.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - Indian J Endocrinol Metab
JT  - Indian journal of endocrinology and metabolism
JID - 101555690
PMC - PMC5240065
OTO - NOTNLM
OT  - Canagliflozin
OT  - glycated hemoglobin
OT  - hypoglycemic agents
OT  - pleiotropic benefits
OT  - sodium-glucose cotransporter 2 inhibitor
OT  - type 2 diabetes mellitus
COIS- Dr. K. M. Prasanna Kumar and Dr. Sujoy Ghosh have received honoraria from Johnson 
      and Johnson Pvt. Ltd., India. Dr. William Canovatchel is an employee of Janssen 
      Research and Development, LLC. Dr. Nishant Garodia and Dr. Sujith Rajashekar are 
      employees of Johnson and Johnson Pvt. Ltd, India. We have no other relevant 
      affiliations or financial interest in or financial conflict with the subject 
      matter or materials discussed in the manuscript apart from those disclosed.
EDAT- 2017/02/22 06:00
MHDA- 2017/02/22 06:01
PMCR- 2017/01/01
CRDT- 2017/02/21 06:00
PHST- 2017/02/21 06:00 [entrez]
PHST- 2017/02/22 06:00 [pubmed]
PHST- 2017/02/22 06:01 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - IJEM-21-196 [pii]
AID - 10.4103/2230-8210.196016 [doi]
PST - ppublish
SO  - Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):196-209. doi: 
      10.4103/2230-8210.196016.